Zhang Mingzi, Tian Zhongkai, Sun Yehong
Department of Pharmacy, Shenzhen Traditional Chinese Medicine Hospital Department of Internal Medicine-Oncology, Second Affiliated Hospital of Jinan University, Shenzhen People's Hospital, Shenzhen, Guangdong, People's Republic of China.
Medicine (Baltimore). 2017 Nov;96(45):e8570. doi: 10.1097/MD.0000000000008570.
The standard treatment for ovarian cancer is chemotherapy with 2 drugs (taxanes and platinum drugs). However, the traditional combination of the 2 drugs has many adverse effects (AEs) and the cancer cells will quickly become resistant to the drugs. Apatinib is a small-molecule antiangiogenic agent which has shown promising therapeutic effects against diverse tumor types, but it still remains unknown whether apatinib has an antitumor effect in patients with ovarian cancer. Herein, we present a successfully treated case of ovarian cancer using chemotherapy and apatinib, in order to demonstrate the effectiveness of this new combined regimen in ovarian cancer.
A 51-year-old Chinese woman presented with ovarian cancer >4.5 years. The disease and the cancer antigen 125 (CA-125) had been controlled well by surgical treatment and following chemotherapy. However, the drugs could not control the disease anymore as the CA-125 level was significantly increasing.
Ovarian cancer.
The patient was treated with apatinib combined with epirubicin. Apatinib was administered orally, at an initial daily dose of 500 mg, and was then reduced to 250 mg qd after the appearance of intolerable hand-foot syndrome (HFS) and oral ulcer. Then, the oral ulcer disappeared and the HFS was controlled by dose adjustment, oral vitamin B6, and hand cream application.
The CA-125 reverted to the normal value after treatment with the new regimen. Magnetic resonance imaging showed that the original tumor lesions had disappeared. Apatinib monotherapy as maintenance therapy was then used to successfully control the cancer with a complete response. Our study is the first, to our knowledge, to report the therapeutic effects of apatinib and epirubicin on ovarian cancer.
Apatinib combined with chemotherapy and apatinib monotherapy as maintenance therapy could be a new therapeutic strategy for ovarian cancer, especially adenocarcinomas.
卵巢癌的标准治疗方法是使用两种药物（紫杉烷类和铂类药物）进行化疗。然而，这两种药物的传统联合使用有许多不良反应，并且癌细胞会很快对药物产生耐药性。阿帕替尼是一种小分子抗血管生成剂，已显示出对多种肿瘤类型有良好的治疗效果，但阿帕替尼对卵巢癌患者是否具有抗肿瘤作用仍不清楚。在此，我们展示了一例使用化疗和阿帕替尼成功治疗的卵巢癌病例，以证明这种新的联合治疗方案对卵巢癌的有效性。
一名51岁的中国女性患卵巢癌超过4.5年。通过手术治疗和后续化疗，疾病和癌抗原125（CA-125）得到了很好的控制。然而，随着CA-125水平显著升高，药物无法再控制病情。
卵巢癌。
患者接受阿帕替尼联合表柔比星治疗。阿帕替尼口服给药，初始每日剂量为500毫克，在出现难以耐受的手足综合征（HFS）和口腔溃疡后，剂量减至250毫克每日一次。然后，口腔溃疡消失，通过剂量调整、口服维生素B6和涂抹护手霜，HFS得到了控制。
采用新方案治疗后，CA-125恢复到正常水平。磁共振成像显示原来的肿瘤病灶已消失。随后使用阿帕替尼单药作为维持治疗成功控制了癌症，达到完全缓解。据我们所知，我们的研究是首个报道阿帕替尼和表柔比星对卵巢癌治疗效果的研究。
阿帕替尼联合化疗以及阿帕替尼单药作为维持治疗可能是卵巢癌，尤其是腺癌的一种新的治疗策略。
